The Pick fold in tau filaments from human MAPT mutants - Report - MDSpire

The Pick fold in tau filaments from human MAPT mutants

  • By

  • Chao Qi

  • Sofia Lövestam

  • Jenny Shi

  • Alexey G. Murzin

  • Sew Peak-Chew

  • Thomas T. Warner

  • Harro Seelaar

  • Patrick W. Cullinane

  • Zane Jaunmuktane

  • John C. van Swieten

  • Sjors H. W. Scheres

  • Michel Goedert

  • July 8, 2026

  • 0 min

Share

Clinical Report: Structural Analysis of the Pick Fold in Tau Filaments

Background

Tauopathies, including frontotemporal dementia and Pick's disease, are characterized by the aggregation of tau protein into filamentous structures. Understanding the structural variations of tau filaments associated with specific MAPT mutations is crucial for elucidating the pathogenesis of these neurodegenerative disorders.

Data Highlights

MutationFilament StructureResolution (Å)
D252VPick fold2.8
ΔG389-I392Pick fold2.3
G272VOpen Pick foldN/A
S320FOpen Pick foldN/A

Key Findings

  • MAPT mutations D252V and ΔG389-I392 produce tau filaments with the Pick fold.
  • G272V and S320F mutations result in a more open variant of the Pick fold.
  • Filaments from individuals with familial frontotemporal dementia show abundant 3R tau-immunoreactive Pick bodies.
  • Western blotting reveals specific tau banding patterns associated with different mutations.
  • Structural analysis aids in understanding the relationship between tau filament morphology and neurodegenerative disease pathology.

Clinical Implications

The identification of specific tau filament structures associated with MAPT mutations may provide insights into the mechanisms underlying tauopathies. This knowledge could inform future research and therapeutic strategies targeting tau aggregation.

Conclusion

The structural analysis of tau filaments enhances our understanding of the molecular basis of tauopathies, particularly in relation to specific MAPT mutations. Further research is needed to explore the implications of these findings in clinical settings.

Related Resources & Content

  1. Acta Neuropathologica, 2023 -- The ∆K281 Mutation in MAPT Linked to the Development of Pick’s Disease
  2. Acta Neuropathologica, 2017 -- The Function of Tau Protein in Health and Disease States
  3. Acta Neuropathologica, 2020 -- Variability in Conformer Populations Influences Unique Phenotypes in Frontotemporal Lobar Degeneration Linked to the MAPT-P301L Mutation
  4. Structures of filaments from Pick’s disease reveal a novel tau protein fold - PMC
  5. Acta Neuropathologica — Tau and TMEM106B Cross-β Helical Filaments in Gray and White Matter of Multiple System Tauopathy Associated with Presenile Dementia
  6. MAPT-Related Frontotemporal Dementia
  7. Structures of filaments from Pick’s disease reveal a novel tau protein fold - PMC
  8. Mutation ∆K281 in MAPT causes Pick’s disease - PMC
  9. Structure-based classification of tauopathies | Nature
  10. Tau filaments with the Alzheimer fold in human MAPT mutants V337M and R406W - PubMed
  11. Tau filaments with the Alzheimer fold in human MAPT mutants V337M and R406W | Nature Structural & Molecular Biology
  12. Distinct tau filament folds in human MAPT mutants P301L and P301T - PMC
  13. Pharmacotherapy for behavioural manifestations in frontotemporal dementia: An expert consensus from the European Reference Network for Rare Neurological Diseases (ERN‐RND) - PMC
  14. Guidance for clinical management of pathogenic variant carriers at elevated genetic risk for ALS/FTD - PubMed
  15. Joint EANM/SNMMI recommendations on the use of Tau PET imaging in Alzheimer's disease
  16. Current Progress and Future Directions in Non-Alzheimer's Disease Tau PET Tracers - PubMed
  17. Exploratory Tau Biomarker Results From a Multiple Ascending-Dose Study of BIIB080 in Alzheimer Disease: A Randomized Clinical Trial - PMC
  18. Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease
  19. Revisiting the therapeutic landscape of tauopathies: assessing the current pipeline and clinical trials - PMC

Original Source(s)

Related Content